GC
SPRY icon

Guggenheim Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Guggenheim Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Buy
20,159
+7,736
+62% +$66.5K ﹤0.01% 1670
2026
Q1 		$99.8K Buy
+12,423
New +$119K ﹤0.01% 1576

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Guggenheim Capital's SPRY Position: Q2 2026 in Review

Guggenheim Capital increased its ARS Pharmaceuticals (SPRY) stake by 62% in Q2 2026, buying an estimated $66.5K and bringing the position to 20,159 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #1670.

Guggenheim Capital first reported a position in SPRY in Q1 2026 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Guggenheim Capital held 20,159 shares of ARS Pharmaceuticals worth $161K as of Q2 2026.
  • Guggenheim Capital bought 7,736 ARS Pharmaceuticals shares in Q2 2026, an estimated $66.5K.
  • ARS Pharmaceuticals made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1670 holding.
  • Guggenheim Capital first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.